Skip to content
New issue

Have a question about this project? Sign up for a free GitHub account to open an issue and contact its maintainers and the community.

By clicking “Sign up for GitHub”, you agree to our terms of service and privacy statement. We’ll occasionally send you account related emails.

Already on GitHub? Sign in to your account

Update lpoxycodone.json #4271

Merged
merged 4 commits into from
Sep 12, 2023
Merged
Changes from all commits
Commits
File filter

Filter by extension

Filter by extension

Conversations
Failed to load comments.
Loading
Jump to
Jump to file
Failed to load files.
Loading
Diff view
Diff view
40 changes: 28 additions & 12 deletions openprescribing/measure_definitions/lpoxycodone.json
Original file line number Diff line number Diff line change
@@ -1,16 +1,25 @@
{
"name": "NHS England Low Priority Treatment - oxycodone and naloxone combination product",
"title": [
"Oxycodone and naloxone combination cost per 1000 patients"
],
"description": [
"Cost of oxycodone and naloxone combination per 1000 patients"
],
"name": "Items which should not routinely be prescribed in primary care - oxycodone and naloxone combination product",
"title": "Oxycodone and naloxone combination cost per 1000 patients",
"description": "Cost of oxycodone and naloxone combination per 1000 patients",
"numerator_short": "Oxycodone and naloxone combination cost (£)",
"denominator_short": "1000 patients",
"why_it_matters": [
"Oxycodone is an opioid analgesic used to treat severe pain. Naloxone is added to reduce constipation. ",
"The combination product is expensive, and the benefit is unclear."
"<p><a href='https://www.england.nhs.uk/long-read/items-which-should-not-routinely-be-prescribed-in-primary-care-policy-guidance/#oxycodone-and-naloxone-combination-product-2017' target='_Blank'>",
"NHS England guidance states</a>:</p>",
"<p><i>Oxycodone and naloxone combination product is used to treat severe pain and can also be used second line in restless legs syndrome. ",
"The opioid antagonist naloxone is added to counteract opioid-induced constipation by blocking the action of oxycodone at opioid receptors in the gut.</p>",
"PrescQIPP CIC has issued a <a href='https://www.prescqipp.info/-oxycodone/naloxone-prolonged-release-tablets/send/105-oxycodone-naloxone-prolonged-release-targinact-tablets/1307-bulletin-56-oxycodone-naloxone-prolonged-release' target='_Blank'>",
"bulletin</a>, which does not identify a benefit of oxycodone and naloxone in a single product over other analgesia (with laxatives if necessary).</p>",
"<p>Due to the significant cost of the oxycodone and naloxone combination product and the unclear role of the combination product in therapy compared with individual products, ",
"the joint clinical working group considered oxycodone and naloxone suitable for inclusion in this guidance.</p></i>",
"<p>NHS England recommend that GPs:",
"<ul>",
"<li>Do not initiate.</li>",
"<li>Deprescribe in patients currently prescribed this medicine.</li>",
"<li>Prescribe only if no other item or intervention is clinically appropriate.</li>",
"<li>Prescribe only if no other item or intervention is available.</li>",
"</ul>"
],
"tags": [
"cost",
Expand All @@ -24,7 +33,14 @@
"low_is_good": true,
"numerator_type": "bnf_cost",
"numerator_bnf_codes_filter": [
"0407020AF # Oxycodone HCl/Naloxone HCl"
"0407020AF # Oxycodone hydrochloride/naloxone hydrochloride"
],
"denominator_type": "list_size"
}
"denominator_type": "list_size",
"authored_by": "[email protected]",
"checked_by": "[email protected]",
"date_reviewed": "2023-09-12",
"next_review": "2025-09-12",
"measure_complexity": "low",
"measure_type": "bnf_code",
"radar_exclude": false
}
Loading